Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0WJ3F
|
|||
| Drug Name |
N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2
|
|||
| Synonyms |
PMID27215781-Compound-39
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Osteoporosis [ICD-11: FB83.0; ICD-10: M85.8] | Patented | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H30N2O3S
|
|||
| Canonical SMILES |
CCN(CC)C1=CC=C(C=C1)CN(C2=CC=C(C=C2)C)S(=O)(=O)C3=CC=C(C=C3)OC
|
|||
| InChI |
1S/C25H30N2O3S/c1-5-26(6-2)22-13-9-21(10-14-22)19-27(23-11-7-20(3)8-12-23)31(28,29)25-17-15-24(30-4)16-18-25/h7-18H,5-6,19H2,1-4H3
|
|||
| InChIKey |
FKEFNETYRMRPCY-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cannabinoid receptor 1 (CB1) | Target Info | . | [1] |
| Cannabinoid receptor 2 (CB2) | Target Info | . | [1] | |
| Target's Patent Info | Cannabinoid receptor 1 (CB1) | Target's Patent Info | [1] | |
| Cannabinoid receptor 2 (CB2) | Target's Patent Info | [1] | ||
| KEGG Pathway | Rap1 signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Retrograde endocannabinoid signaling | ||||
| Panther Pathway | Endogenous cannabinoid signaling | |||
| Pathway Interaction Database | N-cadherin signaling events | |||
| Reactome | Class A/1 (Rhodopsin-like receptors) | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Small Ligand GPCRs | ||||
| BDNF signaling pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.